Reuben Granich

Dr. Reuben Granich


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2018 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
RGReuben Granich
Reuben Granich
SGSomya Gupta
Somya Gupta
BWBrian G Williams
Brian G Williams

1 May 2014 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Open access
RHR. M. G. J. Houben
R. M. G. J. Houben
DDD. W. Dowdy
D. W. Dowdy
AVA. Vassall
A. Vassall
TCT. Cohen
T. Cohen
MNM. P. Nicol
M. P. Nicol
FPFor The Tb MAC Tb-Hiv Meeting Participants
For The Tb MAC Tb-Hiv Meeting Participants
Existing approaches to tuberculosis (TB) control have been no more than partially successful in areas with high human immunodeficiency virus (HIV) prevalence. In the context of increasingly constrained resources, mathematical modelling can augment understanding and support policy for implementing those strategies that are most likely to bring public health and economic benefits. In this paper, we present an overview of past and recent contributions of TB modelling in this key area, and suggest a way forward through a modelling research agenda that supports a more effective response to the TB-HIV epidemic, based on expert discussions at a meeting convened by the TB Modelling and Analysis Consortium. The research agenda identified high-priority areas for future modelling efforts, including 1) the difficult diagnosis and high mortality of TB-HIV; 2) the high risk of disease progression; 3) TB health systems in high HIV prevalence settings; 4) uncertainty in the natural progression of TB-HIV; and 5) combined interventions for TB-HIV. Efficient and rapid progress towards completion of this modelling agenda will require co-ordination between the modelling community and key stakeholders, including advocates, health policy makers, donors and national or regional finance officials. A continuing dialogue will ensure that new results are effectively communicated and new policy-relevant questions are addressed swiftly.

1 November 2018 in The Lancet
Verified
Journal Article
Closed access
RGReuben Granich
Reuben Granich

25 September 2021 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
PDF file
RGReuben Granich
Reuben Granich
SGSomya Gupta
Somya Gupta
BWBrian Williams
Brian Williams
Human immunodeficiency virus (HIV) treatment prevents illness, death, and transmission. The 90-90-90 disease control target is only 73% of people living with HIV virally suppressed. For 2010 to 2019, we abstracted HIV funding data for 40 countries in sub-Saharan Africa (70% of global HIV burden and >99% of HIV burden in the region in 2018). During 2010–2019, there was ∼$52 billion funding for 40 countries (99% Africa HIV burden). Domestic funding ranged from $0 to $3.2 billion. PEPFAR funding was $32 billion (average $1.4 billion; range $0.089–4.3 billion) among 22 countries. Global Fund averaged $306 million ($1.9 million to $1.1 billion) for 40 countries. Among PLHIV, known HIV status averaged 80% (11% to 94%). ART coverage averaged 64% (9% to 90%). Viral suppression among PLHIV ranged from 8% to 87%. Of the 40 countries, 21 reported under 60% of PLHIV to be on treatment and 13 did not report viral suppression for 2018. Achieving 90-90-90 is feasible in challenging settings if resources are used efficiently. Despite the significant investment in the HIV response, many countries have not reached the 90-90-90 target. Greater attention to efficiency and prioritizing important targets will be required to end AIDS in Africa.

31 December 2018 in International Journal of Virology and AIDS
Verified
Journal Article
Open access
RGReuben Granich
Reuben Granich
GSGupta Somya
Gupta Somya
WBWilliams Brian
Williams Brian
Although human immunodeficiency virus (HIV) first came to our attention thirty-seven years ago, the acquired immunodeficiency syndrome (AIDS) which it causes is, without treatment, 100% fatal with devastating consequences for millions of people.

31 December 2018 in International Journal of Virology and AIDS
Verified
Journal Article
Open access
RGReuben Granich
Reuben Granich
GSGupta Somya
Gupta Somya
WMWollmers Matt
Wollmers Matt
RMRuffner Mike
Ruffner Mike
WBWilliams Brian
Williams Brian
HIV remains a major global public health threat with one million HIV-related deaths, two million new infections and over 1 million HIV-associated TB cases each year. However, population-based studies suggest marked declines in incidence, prevalence and deaths in the countries in East and Southern Africa that have expanded antiretroviral treatment (ART) at the fastest rate in the world. Previous research has indicated that most of the positive epidemiologic developments are indeed due to the rapid expansion of ART. However, many modeling groups’ estimates of the impact of ART on these trends vary widely. This calls into question the ART efficacy, effectiveness and coverage parameters that modelers use to project HIV incidence and prevalence.